GRAL
HEALTHCAREGRAIL Inc
Live · NASDAQ · May 9, Close
What's Moving GRAL Today?
No stock-specific AI insight has been generated for GRAL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$62.75
Fundamentals
Trading
GRAL News
22 articles- How The GRAIL (GRAL) Narrative Is Shifting After NHS Galleri Results And Reimbursement QuestionsYahoo Finance·May 8, 2026
- [10-Q] GRAIL, Inc. Quarterly Earnings ReportStock Titan·May 8, 2026
- GRAIL Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- GRAIL Reports First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- GRAIL to Present at the BofA Securities 2026 Health Care ConferenceYahoo Finance·Apr 30, 2026
- Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·Apr 28, 2026
- GRAIL to Announce First Quarter 2026 Financial ResultsYahoo Finance·Apr 22, 2026
- GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- A Look At GRAIL (GRAL) Valuation After New Galleri Integrations With Epic Junction And SuperpowerYahoo Finance·Apr 11, 2026
- GRAIL Partners With Epic to Broaden Galleri Test Access Across USYahoo Finance·Apr 8, 2026
- GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access NationwideYahoo Finance·Apr 7, 2026
- Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early DetectionYahoo Finance·Apr 1, 2026
- Grail (GRAL) Rated Buy by Guggenheim on Galleri PotentialYahoo Finance·Mar 31, 2026
- Here's Why Grail Stock Soared Higher This WeekThe Motley Fool·Mar 26, 2026
- Block upgraded, Starbucks downgraded: Wall Street's top analyst callsYahoo Finance·Mar 18, 2026
- Assessing GRAIL (GRAL) Valuation After Recent Share Price Pullback And Ongoing Growth ChallengesYahoo Finance·Mar 14, 2026
- GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as SuccessorYahoo Finance·Mar 12, 2026
- GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Yahoo Finance·Mar 2, 2026
- Here’s What Analysts Are Saying About Grail Inc. (GRAL)Yahoo Finance·Feb 27, 2026
- GRAIL to Present at the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 24, 2026
- GRAIL (GRAL) Valuation Reassessed After NHS Galleri Trial Setback And Market SelloffYahoo Finance·Feb 23, 2026
- Grail Shares Crashes 50% After Major Cancer Screening Trial Fails Main GoalYahoo Finance·Feb 20, 2026
All 22 articles loaded
Price Data
52-Week Range
$62.75
Fundamentals
Trading
About GRAIL Inc
GRAIL, LLC is a leading biotechnology innovator specializing in groundbreaking blood tests for early cancer detection, leveraging its proprietary genomic technologies to transform the multi-cancer early detection (MCED) landscape. By providing individuals with crucial insights for proactive health management, GRAIL is committed to advancing precision medicine and significantly improving patient outcomes. The company's pioneering efforts aim to fill critical gaps in existing cancer screening and diagnostics, solidifying its position as a vital entity in the evolving oncology sector.